Abeti R et al., 2022-05-19: Combination screen in Friedreich's ataxia cells that included methylene blue alongside the NAD precursor nicotinamide riboside and resveratrol; the combination that worked was dimethyl fumarate plus resveratrol, not methylene blue.
Eight single drug molecules were administered to FA fibroblast patient cells: nicotinamide riboside, hemin, betamethasone, resveratrol, epicatechin, histone deacetylase inhibitor 109, methylene blue, and dimethyl fumarate.
abstract
Abeti R et al., 2022-05-19: Combination screen in Friedreich's ataxia cells that included methylene blue alongside the NAD precursor nicotinamide riboside and resveratrol; the combination that worked was dimethyl fumarate plus resveratrol, not methylene blue. Study type: patient-derived fibroblast screen plus neuronal and cardiomyocyte models plus an FA mouse model. N: patient cell lines and mouse cohorts per paper. Country: UK (UCL) with international collaborators. Dose: single-agent concentrations per paper; methylene blue was one of eight single agents screened. Comparator: untreated cells and each single agent. Funder: not stated in the PubMed record; declared conflicts: none. Directly relevant to C7 because it is a real combination study pairing methylene blue with a NAD precursor (nicotinamide riboside) and with resveratrol – and methylene blue was not part of the effective pair. Study type: lab.
